checkAd

Harrow Sells Non-Ophthalmic Compounding Business

Harrow (Nasdaq: HROW), an eyecare pharmaceutical company exclusively focused on the discovery, development, and commercialization of innovative ophthalmic therapies, today announced the sale of its non‑ophthalmic compounding business to Innovation Compounding Pharmacy, LLC, an affiliate of Revelation Pharma Corporation (“Revelation”).

Pursuant to the terms of the transaction, Revelation purchased the assets of Harrow’s non‑ophthalmic compounding business, including its formulations, customer accounts, and other related assets. The transaction did not involve a pharmaceutical production or dispensing facility. Harrow will continue to support Revelation during an estimated three-month transition period, and Revelation will offer employment to Harrow employees supporting the acquired business.

“This transaction is consistent with Harrow’s strategic vision to focus exclusively on ophthalmic medicines – to be a ‘pure play’ ophthalmic pharmaceuticals company,” said Mark L. Baum, Harrow’s Chairman and Chief Executive Officer. “As we approach several key milestones, including the upcoming commercial launch of recently FDA-approved IHEEZO; the launch of our patent‑pending Fortisite compounded combination antibiotics; the outcome of the MELT‑300 pivotal efficacy study, expected before the end of this year, for one of our former subsidiaries, Melt Pharmaceuticals; progress on product acquisition activities we are pursuing, and new ophthalmic compounded product launches expected in the coming months, we believe this transaction demonstrates our resolve to concentrate on our core competencies and commercial expertise in the North American ophthalmic pharmaceuticals market. Going forward, our capital allocation strategy, including proceeds from this transaction, will be aimed at expanding Harrow’s branded ophthalmic product portfolio.”

About Harrow

Harrow (Nasdaq: HROW) is an eyecare pharmaceutical company exclusively focused on the discovery, development, and commercialization of innovative ophthalmic therapies that are accessible and affordable. For more information about Harrow, including investor-related materials, please visit the corporate website, harrowinc.com, or Harrow’s LinkedIn page.

About Revelation Pharma Corporation

Revelation Pharma is a national network of 503A and 503B compounding pharmacies providing innovative and quality pharmaceutical products and services through “industry best” patient care and solutions for customers. Revelation Pharma is owned by Osceola Capital, a Tampa-based private equity firm that invests in lower middle-market services companies.


The Harrow Health Stock currently trades with a fall of -2,62 % to 11,50USD on the Nasdaq stock exchange.

Wertpapier



0 Kommentare
Nachrichtenquelle: Business Wire (engl.)
 |  101   |   |   

Schreibe Deinen Kommentar

Disclaimer

Harrow Sells Non-Ophthalmic Compounding Business Harrow (Nasdaq: HROW), an eyecare pharmaceutical company exclusively focused on the discovery, development, and commercialization of innovative ophthalmic therapies, today announced the sale of its non‑ophthalmic compounding business to Innovation …

Nachrichten des Autors

181 Leser
167 Leser
135 Leser
129 Leser
125 Leser
124 Leser
116 Leser
115 Leser
115 Leser
109 Leser
700 Leser
352 Leser
286 Leser
283 Leser
255 Leser
252 Leser
245 Leser
237 Leser
235 Leser
217 Leser
1143 Leser
777 Leser
700 Leser
634 Leser
625 Leser
532 Leser
515 Leser
494 Leser
468 Leser
425 Leser
7528 Leser
2918 Leser
2498 Leser
2441 Leser
2161 Leser
2102 Leser
1787 Leser
1699 Leser
1586 Leser
1533 Leser